|Basilea Pharmaceutica AG -- USA Stock|| |
USD 75.68 1.57 2.03%
Head - Corporate DevelopmentWe currently do not have informatin regarding Barbara Zink. This executive tanure with Basilea Pharmaceutica AG is not currenlty determined.
41 61 606 11 11 http://www.basilea.com
The company has return on total asset (ROA)
of (7.18) %
which means that it has lost $7.18 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (4.6) %
meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 197.51 M in total debt. Basilea Pharmaceutica AG has Current Ratio of 2.92 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.
Basilea Pharmaceutica Ltd., together with its subsidiaries, operates as an integrated biopharmaceutical company. Basilea Pharmaceutica AG (BPMUF) is traded on OTC Market in USA. It is located in Basel, and employs 250 people.